The relationship between adiposity and stature in prepubertal children with celiac disease by Nwosu, Benjamin U. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Endocrinology/Diabetes Pediatric Divisions 
2013-10-01 
The relationship between adiposity and stature in prepubertal 
children with celiac disease 
Benjamin U. Nwosu 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/peds_endocrinology 
 Part of the Digestive System Diseases Commons, Endocrinology, Diabetes, and Metabolism 
Commons, Nutritional and Metabolic Diseases Commons, and the Pediatrics Commons 
Repository Citation 
Nwosu BU, Snook RI, Maranda LS. (2013). The relationship between adiposity and stature in prepubertal 
children with celiac disease. Endocrinology/Diabetes. https://doi.org/10.1515/jpem-2012-0312. Retrieved 
from https://escholarship.umassmed.edu/peds_endocrinology/41 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Endocrinology/
Diabetes by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
DOI 10.1515/jpem-2012-0312      J Pediatr Endocr Met 2013; 26(9-10): 819–824
Benjamin Udoka Nwosu*, Rachel I. Snook and Louise Maranda
The relationship between adiposity and stature in 
prepubertal children with celiac disease
Abstract
Background and aim: The pathogenesis of short stature in 
celiac disease (CD) is unknown. Obese children are gener-
ally taller than their non-obese peers; however, the role 
of adiposity on stature in CD is unclear. Our aim was to 
determine the association between adiposity and stature 
in CD.
Subjects and methods: We compared the anthropometric 
characteristics of prepubertal children of ages 3–12 years, 
with biopsy-proven CD (n = 40) and who were not on glu-
ten-free diet, to same aged, prepubertal non-CD children 
(n = 50). Body mass index (BMI) was calculated using the 
formula weight/height2. Sex-adjusted midparental target 
height (MPTH) standard deviation score (SDS) was cal-
culated using National Children Health Statistics data for 
18-year-old adults. Data were expressed as mean ± stand-
ard deviation.
Results: CD subjects had significantly lower BMI SDS 
than controls (0.61 ± 1.22 vs. 1.28 ± 1.60, p = 0.027) but were 
not significantly shorter than the controls (–0.05 ± 1.21 vs. 
0.21 ± 1.71, p = 0.41). When the patients were subdivided 
into the normal-weight and overweight/obese groups, 
the normal-weight CD patients were of similar height 
as the normal-weight controls (p = 0.76) but were signifi-
cantly shorter than both the overweight/obese controls 
(p < 0.001) and overweight/obese CD children (p < 0.001). 
Interestingly, the overweight/obese CD children were 
significantly taller than the normal-weight controls 
(p = 0.003). The MPTH SDS did not differ between the 
groups.
Conclusions: Overweight/obese prepubertal children with 
CD were taller than both their normal-weight CD peers and 
the normal-weight controls, but were of similar height as 
the overweight/obese control subjects.
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Introduction
Celiac disease (CD) is an autoimmune enteropathy that 
affects 0.5%–1% of the population (1). Untreated CD is asso-
ciated with malnutrition in 67% of patients (2). However, 
recent studies indicate that CD and obesity can coexist in 
children and adolescents (3–6) at a reported frequency of 
5%–6% (6, 7) for obesity alone, and up to 19% for both 
overweight and obesity (6). Extraintestinal features such as 
short stature, delayed puberty, and dental enamel defects 
may occur as monosymptomatic manifestations of CD (8). 
In one study, short stature was the leading extraintestinal 
symptom of CD in 30% of 485 children (9). The pathogen-
esis of short stature in CD is unknown (10). Some studies 
report that nutritional deficits lead to impaired growth in 
children with untreated CD (10, 11), whereas others demon-
strate evidence for growth hormone (GH) deficiency (12, 13) 
and GH resistance (14–16) in some patients with CD.
Despite the description of obesity in patients with CD 
(3–6, 17–22), the role of adiposity on stature in prepubertal 
children with CD is unknown. In general, obese or over-
weight children are taller than normal-weight children (23). 
The mechanism of this height differential is unknown. The 
proposed mechanisms for the tall stature include insulin 
stimulation of the insulin-like factor-I receptor (24) and the 
stimulatory effects of leptin on the hypothalamic-pituitary-
gonadal axis (25–27), skeletal growth centers (28), and the 
activity of enzymes essential for the synthesis of adrenal 
androgens (29). Obese children have increased adrenal 
androgen levels (30), and this may be involved in the accel-
erated growth of these children before puberty (31).
The aim of this study was to determine the role of adi-
posity on stature in untreated, prepubertal children with 
CD. Our hypothesis was that overweight/obese prepuber-
tal children with CD would be significantly taller than 
normal-weight CD children.
Subjects and methods
Subjects
Medical records of prepubertal children aged 3–12 years with CD at 
the Children’s Medical Center of the UMass Memorial Medical Center 
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were reviewed and compared with a cohort of healthy prepubertal 
children without CD who participated in a prospective cross-section-
al study of the role of vitamin D in the protection of bone mineral 
content in prepubertal children. The study protocol was approved by 
the University of Massachusetts Institutional Review Board. Study 
subjects (n = 40; 26 females and 14 males) were included if they had 
a diagnosis of CD by intestinal biopsy and if they were not on a glu-
ten-free diet (GFD). All children who carried a diagnosis of CD had 
undergone an endoscopic examination of the upper gastrointestinal 
tract with a variable number of biopsies of the distal duodenal mu-
cosa (32, 33). Infiltrative changes (Marsh type I), crypt hyperplasia 
(Marsh type II), and villous atrophy (Marsh type III) were considered 
characteristic histopathological features of CD (34). Patients were ex-
cluded if they had disorders of the thyroid or adrenal glands, or other 
autoimmune diseases such as type 1 diabetes. Subjects were also ex-
cluded if they had syndromic short stature, GH deficiency, or were in 
puberty as determined by Tanner 2 breast development or greater in 
girls or a testicular volume of  ≥  4 cm3 in boys. Subjects were catego-
rized into either normal weight or overweight and obese using a body 
mass index (BMI) of 5th to  < 85th percentile for normal weight,  > 85th 
but  < 95th percentile for overweight, and  ≥  95th percentile to define 
obesity (35). An age-matched group of healthy prepubertal children 
who participated in a cross-sectional study entitled ‘The Relation-
ship between Vitamin D Deficiency and Low Bone Mineral Content in 
Children’, ClinicalTrails.gov Identifier: NCT0075689, at the Children’s 
Medical Center of the UMass Memorial Medical Center, served as nor-
mal controls. All subjects in the control group were prepubertal (Tan-
ner 1 breast for girls and testicular volume of  < 4 cm3 for boys), not on 
vitamin D or calcium supplementation, and had no medical diseases 
affecting calcium or vitamin D metabolism. All controls were nega-
tive for CD-associated autoantibodies and had no diagnosis of CD. 
This group consisted of 29 overweight/obese (17 males, 12 females) 
and 21 normal-weight (12 males, 9 females) subjects.
Anthropometry
Height was measured to the nearest 0.1  cm using a wall-mounted 
stadiometer (Holtain Ltd., Crymych, Dyfed, UK) that was calibrated 
daily. Weight was measured to the nearest 0.1 kg using an upright 
scale. BMI was derived using the formula weight/height2 (kg/m2), and 
expressed as standard deviation score (SDS) for age and sex based on 
National Center for Health Statistics (NCHS) data (36). Sex-adjusted 
midparental target height (MPTH) SDS was calculated for 18-year-old 
adults using NCHS data and the standard formula for MPTH (37). The 
MPTH is a child’s projected adult height based on the heights of his or 
her parents and is calculated as follows: for girls, the father’s height 
minus 13 cm (5 in) is averaged with the mother’s height; for boys, the 
mother’s height plus 13 cm is averaged with the father’s height (37). 
Anthropometric data were expressed as mean ± SD.
Statistics
Statistical analyses were performed using the SPSS Predictive Ana-
lytics Software v.19 (IBM Corporation, Somers, NY). Means and 
standard deviations were calculated for descriptive summary statis-
tics. Anthropometric measurements were compared using Student’s 
t-test. BMI and sex-adjusted MPTH were expressed as SDS. All data 
were normally distributed.
Results
The baseline characteristics of the study patients and con-
trols are shown in Table 1. The CD subjects were predomi-
nantly of modified Marsh III classification (n = 36; 90%), 
with only three subjects (7.5%) classified as Marsh I and 
one subject (2.5%) as Marsh II. Their modes of presenta-
tion were as follows: diarrhea alone (5%), diarrhea in con-
junction with other gastrointestinal complaints (32.5%), 
abdominal pain (27.5%), short stature (5%), asympto-
matic but detected through family screening for CD and 
other disorders (17.5%), and other (including flatulence, 
abdominal distension, hematochezia, and weight loss) 
(12.5%). Family history of CD was present in nine (22.5%) 
of the CD patients. Of the nine affected families, only two 
fathers and two mothers had CD, whereas the rest of the 
affected family members were either the patients’ siblings 
or grandparents.
Statistical analysis showed that CD subjects had 
significantly lower BMI SDS than controls (0.61 ± 1.22 
vs. 1.28 ± 1.6, p = 0.027) but were not significantly shorter 
than the controls (–0.05 ± 1.21 vs. 0.21 ± 1.71, p = 0.41). 
However, when the patients were subdivided into the 
Table 1 Comparison of the anthropometric characteristics of prepubertal children with celiac disease and normal controls.
Parameter Celiac disease 
(n = 40)
Normal 
(n = 50)
p-Value
Age, years 7.52 ± 2.66 8.02 ± 2.66 0.38
Height SDS –0.05 ± 1.21 0.21 ± 1.71 0.41
Weight SDS 0.322 ± 1.53 1.08 ± 1.96 0.042
BMI SDS 0.61 ± 1.22 1.28 ± 1.60 0.027
MPTH SDS 0.02 ± 0.95 (n = 17) –0.01 ± 0.93 (n = 26) 0.91
Child Ht SDS-MPTH SDS –0.53 ± 1.12 (n = 17) –0.18 ± 1.54 (n = 26) 0.40
SDS, standard deviation score; BMI, body mass index; MPTH, midparental target height.
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Figure 1 Box plots of the comparison of height standard deviation 
scores of patients with celiac disease and normal controls stratified 
by body mass index. This figure shows that the overweight/obese 
controls and overweight/obese children with celiac disease were 
significantly taller than their respective normal-weight peers.
normal-weight and overweight/obese groups (Figure 1), 
the overweight/obese CD patients (n = 17) were taller than 
the normal-weight CD subjects (n = 23) (0.67 ± 0.95 vs. 
–0.58 ± 1.11, p < 0.001), and the overweight/obese controls 
(n = 29) were taller than the normal-weight controls (n = 21) 
(0.88 ± 0.42 vs. –0.71 ± 1.66, p = 0.001). The normal-weight 
CD patients were of similar height as the normal-weight 
controls (–0.58 ± 1.11 vs. –0.71 ± 1.66, p = 0.76), but were sig-
nificantly shorter than both the overweight/obese controls 
(–0.58 ± 1.11 vs. 0.88 ± 0.42, p < 0.001) and the overweight/
obese CD children (–0.58 ± 1.11 vs. 0.67 ± 0.95, p < 0.001). 
The overweight/obese CD children and overweight/obese 
controls had similar height SDS (0.67 ± 0.95 vs. 0.88 ± 0.42, 
p = 0.56). The MPTHs did not differ between these two 
groups. There was no age difference between the nor-
mal-weight and overweight/obese CD patients (7.0 ± 2.26 
vs. 8.22 ± 3.06, p = 0.18), nor between the normal-weight 
and overweight/obese controls (7.28 ± 2.42 vs. 8.56 ± 2.74, 
p = 0.0.08).
Interestingly, the overweight/obese CD patients had 
a significantly lower BMI SDS than the overweight/obese 
controls (1.71 ± 0.45 vs. 2.37 ± 0.89, p = 0.002), as well as a 
significantly lower weight SDS (1.63 ± 0.69 vs. 2.36 ± 1.08, 
p = 0.008), but had similar height SDS (0.67 ± 0.95 vs. 
0.88 ± 0.42, p = 0.56). There was no difference in BMI SDS 
between the normal-weight controls and the normal-
weight CD children (–0.23 ± 1.03 vs. –0.21 ± 0.93, p = 0.93). 
As expected from the study design, the overweight/obese 
controls had significantly greater BMI SDS than both 
the normal-weight controls (2.37 ± 0.89 vs. –0.23 ± 1.03 
p < 0.001) and the normal-weight CD patients (2.37 ± 0.89 
vs. –0.21 ± 0.93, p < 0.001).
Further analysis for the associations between 
tissue transglutaminase IgA antibody level and BMI 
SDS, height SDS, and weight SDS, separately, showed 
no linear relationships between transglutaminase 
antibody level and these anthropometric parameters. 
The non-significant β coefficients were as follows: 
BMI (β = –0.22, p = 0.21), height SDS (β = –0.12, p = 0.31), 
and weight SDS (β = –0.25, p = 0.15). The adjusted R2 
was  < 0.035 for all three parameters, which was consist-
ent with the absence of linear relationships between 
tissue transglutaminase IgA antibody and the anthro-
pometric parameters.
Discussion
This study showed that overweight/obese prepubertal 
children were taller than their normal-weight peers irre-
spective of whether they had CD or were healthy. The 
normal-weight CD children had similar height as the 
normal-weight controls, but were significantly shorter 
than both the overweight/obese controls and the over-
weight/obese CD children. The overweight/obese CD 
patients had significantly lower BMI and weight SDS 
than the overweight/obese controls. Height SDS was 
similar between the overweight/obese CD children and 
the overweight/obese controls. The MPTHs were similar 
for the CD and non-CD children.
The findings from this study on the association 
between height and adiposity in children are similar 
to earlier studies carried out in healthy children in 
the US (38, 39), Australia (40), and Japan (41). Despite 
the cross-cultural reproducibility of these findings in 
normal children, this phenomenon of height difference 
based on the degree of adiposity in children has not 
been studied in prepubertal children with CD. Freed-
man et  al. (42) employed a cross-sectional study to 
investigate the relationships between height and BMI, 
skin fold thickness, and percentage body fat determined 
by dual-energy X-ray absorptiometry in 5–18-year-old 
subjects (n = 1180) and found that obesity was substan-
tially higher among 5–11-year-old subjects who were 
relatively tall for their age than among shorter children. 
Among 5–8-year-old boys, each SD increase in height-
for-age was associated with a 4.6-fold increase in the 
prevalence of obesity (p < 0.001), and the subjects’ 
heights were correlated with BMI, skinfold thickness, 
and percentage body fat.
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Cheng et al. (43) investigated the effect of the degree 
of villous atrophy on BMI and reported that the under-
weight and normal-weight CD patients had a significantly 
higher rate of more severe villous atrophy (Marsh III b/c) 
than Marsh IIIa. Patients with a Marsh IIIa pathology 
had a significantly higher BMI than those with a Marsh 
IIIb/c pathology (p = 0.004). Thus, it is possible that less 
severe degrees of villous atrophy could enhance the 
accumulation or the preservation of body fat. Reilly et al. 
(6) studied the effects of GFD on anthropometric char-
acteristics of patients with CD and followed the patients 
for a mean duration of 35.6 months. They found that 
75% of patients with elevated BMI at diagnosis experi-
enced a significant decrease in their BMI SDS, with 44% 
of subjects achieving normal BMI status. In contrast, 
patients with normal BMI SDS at diagnosis experienced 
a significant increase in BMI SDS, with 13% of the sub-
jects becoming overweight. A remarkable finding from 
our study was that the overweight/obese CD patients 
had a significantly lower BMI and weight SDS than the 
overweight/obese controls. This is suggestive of relative 
malabsorption in the overweight/obese CD patients at 
diagnosis. Although the serum concentrations of trans-
glutaminase IgA antibody have been correlated with the 
degree of intestinal injury in CD, we found no relation-
ships between tissue transglutaminase IgA antibody 
levels and anthropometric parameters such as height, 
weight, and BMI. However, our finding may be applica-
ble to only Marsh III category disease, as 90% of our CD 
patients had modified Marsh III score.
The mechanism of the height difference between 
normal-weight and overweight/obese children is unclear. 
One proposed mechanism involves the stimulation of 
the insulin-like factor-I receptor by elevated levels of 
circulating insulin in obese children (24). Leptin is also 
believed to play a central role in the effect of adiposity 
on stature (23). Ertekin et al. (44) found that in children 
with CD, leptin levels were not only correlated with base-
line BMI but were also significantly reduced in active CD, 
and increased significantly following GFD, in parallel 
with increasing BMI (44). Studies that reported increased 
adrenal androgen levels in obese children (30) also 
showed that these children frequently show an increase 
in height velocity with tall stature for age (31) despite low 
or variable levels of GH, insulin-like growth factor-I, and 
GH binding protein (45).
The unique strength of this study is that it was con-
ducted exclusively in prepubertal children. Studies 
in prepubertal children are a better guide to potential 
causal associations than studies in pubertal or post-
pubertal subjects because associations in childhood 
are less prone to confounding physiologic and lifestyle 
factors, such as the different stages of pubertal matura-
tion and the effects of fluctuations in pubertal hormone 
levels on adiposity. This prepubertal cohort represents 
the youngest group of subjects in whom the association 
between adiposity and height in CD could be demon-
strated. The robust group of healthy prepubertal chil-
dren in the control group ensured the validity of the 
anthropometric comparisons. Furthermore, the results 
were adjusted for MPTH to exclude the effects of genetic 
causes of short stature.
This study has some limitations. First, the cross-sec-
tional study design limited causal inference about the 
effects of adiposity on stature in CD. The relatively small 
sample size could have precluded the detection of subtle 
differences between the groups. Bone age data were not 
available for our cohort. It is possible that obesity could 
lead to bone age advancement and possibly contribute 
to the height differential between normal-weight and 
overweight/obese children. However, this is unlikely in a 
cohort of prepubertal children. Our cohort predominantly 
had modified Marsh III disease; therefore, our results may 
not be generalizable to patients with the less severe forms 
of the disease.
In conclusion, this study showed that overweight/
obese prepubertal children with CD were taller than 
their normal-weight peers with CD. This finding, which 
has previously been demonstrated in healthy children, 
suggests that less severe forms of CD could permit the 
accumulation of fat tissue, which promotes statural 
growth. Further studies examining the roles of leptin, 
insulin, and adrenal androgens on stature in CD are 
warranted.
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